BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37295130)

  • 1. Association between pertussis vaccination coverage and other sociodemographic factors and pertussis incidence using surveillance data.
    Rane MS; Wakefield J; Rohani P; Halloran ME
    Epidemics; 2023 Sep; 44():100689. PubMed ID: 37295130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating Population-Level Effects of the Acellular Pertussis Vaccine Using Routinely Collected Immunization Data.
    Rane MS; Halloran ME
    Clin Infect Dis; 2021 Dec; 73(11):2101-2107. PubMed ID: 33881527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Diphtheria-Tetanus-Acellular Pertussis Vaccine Timeliness and Number of Doses With Age-Specific Pertussis Risk in Infants and Young Children.
    Rane MS; Rohani P; Halloran ME
    JAMA Netw Open; 2021 Aug; 4(8):e2119118. PubMed ID: 34374773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to pneumococcal conjugate vaccination schedule and uptake rate as compared to the established diphtheria-tetanus-acellular pertussis vaccination in Cyprus.
    Hadjipanayis A; Efstathiou E; Michaelidou K; Papaevangelou V
    Vaccine; 2018 Sep; 36(38):5685-5691. PubMed ID: 30115523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of Immunity and Effectiveness of Diphtheria-Tetanus-Acellular Pertussis Vaccines in Children.
    Domenech de Cellès M; Rohani P; King AA
    JAMA Pediatr; 2019 Jun; 173(6):588-594. PubMed ID: 31009031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waning Tdap Effectiveness in Adolescents.
    Klein NP; Bartlett J; Fireman B; Baxter R
    Pediatrics; 2016 Mar; 137(3):e20153326. PubMed ID: 26908667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine in Adults in Japan.
    Ujiie M; Tsuzuki S; Suzuki M; Ota M; Suzuki T; Nomoto H; Yamamoto K; Saito S; Kokaze A; Kinoshita N
    Jpn J Infect Dis; 2021 Sep; 74(5):399-404. PubMed ID: 33518629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
    Martinón-Torres F; Halperin SA; Nolan T; Tapiéro B; Perrett KP; de la Cueva IS; García-Sicilia J; Stranak Z; Vanderkooi OG; Kosina P; Rumlarova S; Virta M; Arribas JMM; Miranda-Valdivieso M; Novas BA; Bozensky J; Ortega MJC; Amador JTR; Baca M; Palomino EE; Zuccotti GV; Janota J; Marchisio PG; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Mesaros N
    Vaccine; 2021 Mar; 39(11):1598-1608. PubMed ID: 33612341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.
    Misegades LK; Winter K; Harriman K; Talarico J; Messonnier NE; Clark TA; Martin SW
    JAMA; 2012 Nov; 308(20):2126-32. PubMed ID: 23188029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of pertussis and Haemophilus influenzae type b disease in Canada with exclusive use of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b pediatric combination vaccine and an adolescent-adult tetanus-diphtheria-acellular pertussis vaccine: implications for disease prevention in the United States.
    Greenberg DP; Doemland M; Bettinger JA; Scheifele DW; Halperin SA; ; Waters V; Kandola K
    Pediatr Infect Dis J; 2009 Jun; 28(6):521-8. PubMed ID: 19436236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertussis epidemic despite high levels of vaccination coverage with acellular pertussis vaccine.
    Sala-Farré MR; Arias-Varela C; Recasens-Recasens A; Simó-Sanahuja M; Muñoz-Almagro C; Pérez-Jové J
    Enferm Infecc Microbiol Clin; 2015 Jan; 33(1):27-31. PubMed ID: 24216286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acellular Pertussis Vaccine Effectiveness Over Time.
    Zerbo O; Bartlett J; Goddard K; Fireman B; Lewis E; Klein NP
    Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31182549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies.
    Broset E; Pardo-Seco J; Kanno AI; Aguilo N; Dacosta AI; Rivero-Calle I; Gonzalo-Asensio J; Locht C; Leite LCC; Martin C; Martinón-Torres F
    EBioMedicine; 2021 Mar; 65():103254. PubMed ID: 33711798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.